Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale

485
16
Favorite

Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale

seekingalpha2022-05-03

JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

485

Report

Comment（16）

YJ1234
·2022-05-04
Ok
Reply
1
Report
YJ1234
·2022-05-04
Ok
Reply
1
Report
YauDK
·2022-05-04
Ye ye
Reply
2
Report
InvisibleP
·2022-05-04
Ok
Reply
1
Report
xinxino
·2022-05-04
Ok
Reply
3
Report
ramius75
·2022-05-04
👍
Reply
3
Report
EugeneH
·2022-05-04
Help to like
Reply
4
Report
YMF808
·2022-05-04
Wow
Reply
4
Report
Mic6226
·2022-05-04
Good
Reply
3
Report
MachineGun
·2022-05-04
Ok
Reply
1
Report
逢場作戲又一日
·2022-05-04
Great
Reply
2
Report
BBBBBBBBBB
·2022-05-04
G
Reply
3
Report
nsk
·2022-05-03
Great
Reply
2
Report
Anni001
·2022-05-03
Please like. Thanks
Reply
2
Report
HermioneG
·2022-05-03
Awesome!
Reply
3
Report
huaigim
·2022-05-03
Awesome
Reply
2
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2232305878?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-05-03 21:25","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2232305878","market":"us","top_or_hot":-1,"title":"Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale","media":"seekingalpha","content":"<div>\n<p>JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives ...</p>\n\n<a href=\"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-03 21:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives ...</p>\n\n<a href=\"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale","article_id":"2232305878","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2232305878","pubTimestamp":1651584358,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market ","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技"},"translate_title":"赛森生物股价上涨16%，计划探索包括出售在内的战略选择","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SESN":1},"content_text":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9061600235,"gmtCreate":1651619700518,"gmtModify":1676534934991,"author":{"id":"3569451715493894","authorId":"3569451715493894","name":"YJ1234","avatar":"https://static.tigerbbs.com/da7bfb74470f0f05e980715d2cba26f6","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3569451715493894","authorIdStr":"3569451715493894"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9061600235","repostId":2232305878,"repostType":4,"repost":{"id":"2232305878","pubTimestamp":1651584358,"share":"https://ttm.financial/m/news/2232305878?lang=&edition=fundamental","pubTime":"2022-05-03 21:25","market":"us","language":"en","title":"Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2232305878","media":"seekingalpha","summary":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market ","content":"<html><head></head><body><p></p><p><img src=\"https://static.tigerbbs.com/f4133d165fd1a3872dd4415261977beb\" tg-width=\"750\" tg-height=\"456\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>JuSun/iStock via Getty Images</p><p></p><p>The shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.</p><p><img src=\"https://static.tigerbbs.com/b5783201e2cd8e136a3caa6ee0710d7c\" tg-width=\"868\" tg-height=\"646\" width=\"100%\" height=\"auto\"/></p><p>“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.</p><p>In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.</p><p>Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.</p><p>As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-03 21:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives ...</p>\n\n<a href=\"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2232305878","content_text":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9061877480,"gmtCreate":1651619683995,"gmtModify":1676534934975,"author":{"id":"3569451715493894","authorId":"3569451715493894","name":"YJ1234","avatar":"https://static.tigerbbs.com/da7bfb74470f0f05e980715d2cba26f6","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3569451715493894","authorIdStr":"3569451715493894"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9061877480","repostId":2232305878,"repostType":4,"repost":{"id":"2232305878","pubTimestamp":1651584358,"share":"https://ttm.financial/m/news/2232305878?lang=&edition=fundamental","pubTime":"2022-05-03 21:25","market":"us","language":"en","title":"Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2232305878","media":"seekingalpha","summary":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market ","content":"<html><head></head><body><p></p><p><img src=\"https://static.tigerbbs.com/f4133d165fd1a3872dd4415261977beb\" tg-width=\"750\" tg-height=\"456\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>JuSun/iStock via Getty Images</p><p></p><p>The shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.</p><p><img src=\"https://static.tigerbbs.com/b5783201e2cd8e136a3caa6ee0710d7c\" tg-width=\"868\" tg-height=\"646\" width=\"100%\" height=\"auto\"/></p><p>“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.</p><p>In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.</p><p>Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.</p><p>As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-03 21:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives ...</p>\n\n<a href=\"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2232305878","content_text":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9061875781,"gmtCreate":1651619566228,"gmtModify":1676534934924,"author":{"id":"3580072870029753","authorId":"3580072870029753","name":"YauDK","avatar":"https://static.tigerbbs.com/4e00c10df4000c04392220903422d15f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3580072870029753","authorIdStr":"3580072870029753"},"htmlText":"Ye ye&nbsp;","listText":"Ye ye&nbsp;","text":"Ye ye","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9061875781","repostId":2232305878,"repostType":4,"repost":{"id":"2232305878","pubTimestamp":1651584358,"share":"https://ttm.financial/m/news/2232305878?lang=&edition=fundamental","pubTime":"2022-05-03 21:25","market":"us","language":"en","title":"Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2232305878","media":"seekingalpha","summary":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market ","content":"<html><head></head><body><p></p><p><img src=\"https://static.tigerbbs.com/f4133d165fd1a3872dd4415261977beb\" tg-width=\"750\" tg-height=\"456\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>JuSun/iStock via Getty Images</p><p></p><p>The shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.</p><p><img src=\"https://static.tigerbbs.com/b5783201e2cd8e136a3caa6ee0710d7c\" tg-width=\"868\" tg-height=\"646\" width=\"100%\" height=\"auto\"/></p><p>“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.</p><p>In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.</p><p>Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.</p><p>As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-03 21:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives ...</p>\n\n<a href=\"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2232305878","content_text":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9061879876,"gmtCreate":1651619101991,"gmtModify":1676534934817,"author":{"id":"3585470994468822","authorId":"3585470994468822","name":"InvisibleP","avatar":"https://static.itradeup.com/news/13510d2c4ac014319931fb49792d17eb","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3585470994468822","authorIdStr":"3585470994468822"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9061879876","repostId":2232305878,"repostType":4,"repost":{"id":"2232305878","pubTimestamp":1651584358,"share":"https://ttm.financial/m/news/2232305878?lang=&edition=fundamental","pubTime":"2022-05-03 21:25","market":"us","language":"en","title":"Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2232305878","media":"seekingalpha","summary":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market ","content":"<html><head></head><body><p></p><p><img src=\"https://static.tigerbbs.com/f4133d165fd1a3872dd4415261977beb\" tg-width=\"750\" tg-height=\"456\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>JuSun/iStock via Getty Images</p><p></p><p>The shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.</p><p><img src=\"https://static.tigerbbs.com/b5783201e2cd8e136a3caa6ee0710d7c\" tg-width=\"868\" tg-height=\"646\" width=\"100%\" height=\"auto\"/></p><p>“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.</p><p>In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.</p><p>Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.</p><p>As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-03 21:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives ...</p>\n\n<a href=\"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2232305878","content_text":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9061855644,"gmtCreate":1651618026717,"gmtModify":1676534934489,"author":{"id":"4113646398298622","authorId":"4113646398298622","name":"xinxino","avatar":"https://community-static.tradeup.com/news/48bdb4fe291ddcf6f54b11be84bf4dfd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4113646398298622","authorIdStr":"4113646398298622"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9061855644","repostId":2232305878,"repostType":4,"repost":{"id":"2232305878","pubTimestamp":1651584358,"share":"https://ttm.financial/m/news/2232305878?lang=&edition=fundamental","pubTime":"2022-05-03 21:25","market":"us","language":"en","title":"Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2232305878","media":"seekingalpha","summary":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market ","content":"<html><head></head><body><p></p><p><img src=\"https://static.tigerbbs.com/f4133d165fd1a3872dd4415261977beb\" tg-width=\"750\" tg-height=\"456\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>JuSun/iStock via Getty Images</p><p></p><p>The shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.</p><p><img src=\"https://static.tigerbbs.com/b5783201e2cd8e136a3caa6ee0710d7c\" tg-width=\"868\" tg-height=\"646\" width=\"100%\" height=\"auto\"/></p><p>“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.</p><p>In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.</p><p>Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.</p><p>As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-03 21:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives ...</p>\n\n<a href=\"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2232305878","content_text":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9061825579,"gmtCreate":1651617250127,"gmtModify":1676534934215,"author":{"id":"3586470645934044","authorId":"3586470645934044","name":"ramius75","avatar":"https://community-static.tradeup.com/news/9bf23146914ff935921288dd903ce4fa","vip":1,"crmLevel":5,"crmLevelSwitch":1,"idStr":"3586470645934044","authorIdStr":"3586470645934044"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9061825579","repostId":2232305878,"repostType":4,"repost":{"id":"2232305878","pubTimestamp":1651584358,"share":"https://ttm.financial/m/news/2232305878?lang=&edition=fundamental","pubTime":"2022-05-03 21:25","market":"us","language":"en","title":"Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2232305878","media":"seekingalpha","summary":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market ","content":"<html><head></head><body><p></p><p><img src=\"https://static.tigerbbs.com/f4133d165fd1a3872dd4415261977beb\" tg-width=\"750\" tg-height=\"456\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>JuSun/iStock via Getty Images</p><p></p><p>The shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.</p><p><img src=\"https://static.tigerbbs.com/b5783201e2cd8e136a3caa6ee0710d7c\" tg-width=\"868\" tg-height=\"646\" width=\"100%\" height=\"auto\"/></p><p>“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.</p><p>In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.</p><p>Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.</p><p>As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-03 21:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives ...</p>\n\n<a href=\"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2232305878","content_text":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9061865130,"gmtCreate":1651616055112,"gmtModify":1676534933970,"author":{"id":"3580273334777387","authorId":"3580273334777387","name":"EugeneH","avatar":"https://static.tigerbbs.com/615153c828f3d40a5db402358c9f90f8","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3580273334777387","authorIdStr":"3580273334777387"},"htmlText":"Help to like","listText":"Help to like","text":"Help to like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9061865130","repostId":2232305878,"repostType":4,"repost":{"id":"2232305878","pubTimestamp":1651584358,"share":"https://ttm.financial/m/news/2232305878?lang=&edition=fundamental","pubTime":"2022-05-03 21:25","market":"us","language":"en","title":"Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2232305878","media":"seekingalpha","summary":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market ","content":"<html><head></head><body><p></p><p><img src=\"https://static.tigerbbs.com/f4133d165fd1a3872dd4415261977beb\" tg-width=\"750\" tg-height=\"456\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>JuSun/iStock via Getty Images</p><p></p><p>The shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.</p><p><img src=\"https://static.tigerbbs.com/b5783201e2cd8e136a3caa6ee0710d7c\" tg-width=\"868\" tg-height=\"646\" width=\"100%\" height=\"auto\"/></p><p>“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.</p><p>In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.</p><p>Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.</p><p>As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-03 21:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives ...</p>\n\n<a href=\"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2232305878","content_text":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9061887752,"gmtCreate":1651614959647,"gmtModify":1676534933813,"author":{"id":"4087173082353320","authorId":"4087173082353320","name":"YMF808","avatar":"https://static.tigerbbs.com/4baafafa8982b2c0a7b4c828a5e3cbfb","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087173082353320","authorIdStr":"4087173082353320"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9061887752","repostId":2232305878,"repostType":4,"repost":{"id":"2232305878","pubTimestamp":1651584358,"share":"https://ttm.financial/m/news/2232305878?lang=&edition=fundamental","pubTime":"2022-05-03 21:25","market":"us","language":"en","title":"Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2232305878","media":"seekingalpha","summary":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market ","content":"<html><head></head><body><p></p><p><img src=\"https://static.tigerbbs.com/f4133d165fd1a3872dd4415261977beb\" tg-width=\"750\" tg-height=\"456\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>JuSun/iStock via Getty Images</p><p></p><p>The shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.</p><p><img src=\"https://static.tigerbbs.com/b5783201e2cd8e136a3caa6ee0710d7c\" tg-width=\"868\" tg-height=\"646\" width=\"100%\" height=\"auto\"/></p><p>“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.</p><p>In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.</p><p>Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.</p><p>As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-03 21:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives ...</p>\n\n<a href=\"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2232305878","content_text":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9061815945,"gmtCreate":1651612197860,"gmtModify":1676534933456,"author":{"id":"4109843165472380","authorId":"4109843165472380","name":"Mic6226","avatar":"https://community-static.tradeup.com/news/642ea3ba3ea408756b94df1fc4fc2d69","vip":1,"hat":"https://static.tigerbbs.com/50a4c8d97279fa9f8f1fa9749a6bdff4","crmLevel":7,"crmLevelSwitch":1,"idStr":"4109843165472380","authorIdStr":"4109843165472380"},"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9061815945","repostId":2232305878,"repostType":4,"repost":{"id":"2232305878","pubTimestamp":1651584358,"share":"https://ttm.financial/m/news/2232305878?lang=&edition=fundamental","pubTime":"2022-05-03 21:25","market":"us","language":"en","title":"Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2232305878","media":"seekingalpha","summary":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market ","content":"<html><head></head><body><p></p><p><img src=\"https://static.tigerbbs.com/f4133d165fd1a3872dd4415261977beb\" tg-width=\"750\" tg-height=\"456\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>JuSun/iStock via Getty Images</p><p></p><p>The shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.</p><p><img src=\"https://static.tigerbbs.com/b5783201e2cd8e136a3caa6ee0710d7c\" tg-width=\"868\" tg-height=\"646\" width=\"100%\" height=\"auto\"/></p><p>“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.</p><p>In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.</p><p>Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.</p><p>As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-03 21:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives ...</p>\n\n<a href=\"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2232305878","content_text":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9061816594,"gmtCreate":1651611934232,"gmtModify":1676534933422,"author":{"id":"3581579780416432","authorId":"3581579780416432","name":"MachineGun","avatar":"https://static.tigerbbs.com/b2a731c3f57f68f2ebe7e41ebb718913","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581579780416432","authorIdStr":"3581579780416432"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9061816594","repostId":2232305878,"repostType":4,"repost":{"id":"2232305878","pubTimestamp":1651584358,"share":"https://ttm.financial/m/news/2232305878?lang=&edition=fundamental","pubTime":"2022-05-03 21:25","market":"us","language":"en","title":"Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2232305878","media":"seekingalpha","summary":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market ","content":"<html><head></head><body><p></p><p><img src=\"https://static.tigerbbs.com/f4133d165fd1a3872dd4415261977beb\" tg-width=\"750\" tg-height=\"456\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>JuSun/iStock via Getty Images</p><p></p><p>The shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.</p><p><img src=\"https://static.tigerbbs.com/b5783201e2cd8e136a3caa6ee0710d7c\" tg-width=\"868\" tg-height=\"646\" width=\"100%\" height=\"auto\"/></p><p>“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.</p><p>In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.</p><p>Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.</p><p>As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-03 21:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives ...</p>\n\n<a href=\"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2232305878","content_text":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9061838798,"gmtCreate":1651600357371,"gmtModify":1676534933212,"author":{"id":"3555043402922696","authorId":"3555043402922696","name":"逢場作戲又一日","avatar":"https://community-static.tradeup.com/news/6a5fbf2ceb7c7ee0399d41e6348dadf7","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":4,"crmLevelSwitch":1,"idStr":"3555043402922696","authorIdStr":"3555043402922696"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9061838798","repostId":2232305878,"repostType":4,"repost":{"id":"2232305878","pubTimestamp":1651584358,"share":"https://ttm.financial/m/news/2232305878?lang=&edition=fundamental","pubTime":"2022-05-03 21:25","market":"us","language":"en","title":"Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2232305878","media":"seekingalpha","summary":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market ","content":"<html><head></head><body><p></p><p><img src=\"https://static.tigerbbs.com/f4133d165fd1a3872dd4415261977beb\" tg-width=\"750\" tg-height=\"456\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>JuSun/iStock via Getty Images</p><p></p><p>The shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.</p><p><img src=\"https://static.tigerbbs.com/b5783201e2cd8e136a3caa6ee0710d7c\" tg-width=\"868\" tg-height=\"646\" width=\"100%\" height=\"auto\"/></p><p>“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.</p><p>In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.</p><p>Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.</p><p>As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-03 21:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives ...</p>\n\n<a href=\"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2232305878","content_text":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9061898926,"gmtCreate":1651595302610,"gmtModify":1676534932969,"author":{"id":"3581562365927542","authorId":"3581562365927542","name":"BBBBBBBBBB","avatar":"https://static.tigerbbs.com/973395458d7e1db24dbd4a689c79e8a2","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3581562365927542","authorIdStr":"3581562365927542"},"htmlText":"G","listText":"G","text":"G","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9061898926","repostId":2232305878,"repostType":4,"repost":{"id":"2232305878","pubTimestamp":1651584358,"share":"https://ttm.financial/m/news/2232305878?lang=&edition=fundamental","pubTime":"2022-05-03 21:25","market":"us","language":"en","title":"Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2232305878","media":"seekingalpha","summary":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market ","content":"<html><head></head><body><p></p><p><img src=\"https://static.tigerbbs.com/f4133d165fd1a3872dd4415261977beb\" tg-width=\"750\" tg-height=\"456\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>JuSun/iStock via Getty Images</p><p></p><p>The shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.</p><p><img src=\"https://static.tigerbbs.com/b5783201e2cd8e136a3caa6ee0710d7c\" tg-width=\"868\" tg-height=\"646\" width=\"100%\" height=\"auto\"/></p><p>“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.</p><p>In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.</p><p>Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.</p><p>As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-03 21:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives ...</p>\n\n<a href=\"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2232305878","content_text":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9061808593,"gmtCreate":1651593186879,"gmtModify":1676534932680,"author":{"id":"3566130979400930","authorId":"3566130979400930","name":"nsk","avatar":"https://static.tigerbbs.com/ca5161a1cfd9f69617bbe604d09aa849","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3566130979400930","authorIdStr":"3566130979400930"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9061808593","repostId":2232305878,"repostType":4,"repost":{"id":"2232305878","pubTimestamp":1651584358,"share":"https://ttm.financial/m/news/2232305878?lang=&edition=fundamental","pubTime":"2022-05-03 21:25","market":"us","language":"en","title":"Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2232305878","media":"seekingalpha","summary":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market ","content":"<html><head></head><body><p></p><p><img src=\"https://static.tigerbbs.com/f4133d165fd1a3872dd4415261977beb\" tg-width=\"750\" tg-height=\"456\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>JuSun/iStock via Getty Images</p><p></p><p>The shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.</p><p><img src=\"https://static.tigerbbs.com/b5783201e2cd8e136a3caa6ee0710d7c\" tg-width=\"868\" tg-height=\"646\" width=\"100%\" height=\"auto\"/></p><p>“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.</p><p>In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.</p><p>Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.</p><p>As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-03 21:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives ...</p>\n\n<a href=\"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2232305878","content_text":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9061803600,"gmtCreate":1651592880508,"gmtModify":1676534932631,"author":{"id":"3581489684162254","authorId":"3581489684162254","name":"Anni001","avatar":"https://static.itradeup.com/news/d5be87dbe18cee1e85c9c2cb39fe99ce","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581489684162254","authorIdStr":"3581489684162254"},"htmlText":"Please like. Thanks&nbsp;","listText":"Please like. Thanks&nbsp;","text":"Please like. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9061803600","repostId":2232305878,"repostType":4,"repost":{"id":"2232305878","pubTimestamp":1651584358,"share":"https://ttm.financial/m/news/2232305878?lang=&edition=fundamental","pubTime":"2022-05-03 21:25","market":"us","language":"en","title":"Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2232305878","media":"seekingalpha","summary":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market ","content":"<html><head></head><body><p></p><p><img src=\"https://static.tigerbbs.com/f4133d165fd1a3872dd4415261977beb\" tg-width=\"750\" tg-height=\"456\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>JuSun/iStock via Getty Images</p><p></p><p>The shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.</p><p><img src=\"https://static.tigerbbs.com/b5783201e2cd8e136a3caa6ee0710d7c\" tg-width=\"868\" tg-height=\"646\" width=\"100%\" height=\"auto\"/></p><p>“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.</p><p>In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.</p><p>Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.</p><p>As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-03 21:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives ...</p>\n\n<a href=\"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2232305878","content_text":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9061182405,"gmtCreate":1651586709430,"gmtModify":1676534931142,"author":{"id":"3581581151725380","authorId":"3581581151725380","name":"HermioneG","avatar":"https://static.tigerbbs.com/449ae31dcb8cfcd4dcedab9bc5dec8aa","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581581151725380","authorIdStr":"3581581151725380"},"htmlText":"Awesome!","listText":"Awesome!","text":"Awesome!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9061182405","repostId":2232305878,"repostType":4,"repost":{"id":"2232305878","pubTimestamp":1651584358,"share":"https://ttm.financial/m/news/2232305878?lang=&edition=fundamental","pubTime":"2022-05-03 21:25","market":"us","language":"en","title":"Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2232305878","media":"seekingalpha","summary":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market ","content":"<html><head></head><body><p></p><p><img src=\"https://static.tigerbbs.com/f4133d165fd1a3872dd4415261977beb\" tg-width=\"750\" tg-height=\"456\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>JuSun/iStock via Getty Images</p><p></p><p>The shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.</p><p><img src=\"https://static.tigerbbs.com/b5783201e2cd8e136a3caa6ee0710d7c\" tg-width=\"868\" tg-height=\"646\" width=\"100%\" height=\"auto\"/></p><p>“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.</p><p>In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.</p><p>Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.</p><p>As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-03 21:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives ...</p>\n\n<a href=\"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2232305878","content_text":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9061110449,"gmtCreate":1651584781298,"gmtModify":1676534930813,"author":{"id":"3581567062635546","authorId":"3581567062635546","name":"huaigim","avatar":"https://static.tigerbbs.com/66751ea97b719c58cc4d85f52dee08be","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581567062635546","authorIdStr":"3581567062635546"},"htmlText":"Awesome&nbsp;","listText":"Awesome&nbsp;","text":"Awesome","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9061110449","repostId":2232305878,"repostType":4,"repost":{"id":"2232305878","pubTimestamp":1651584358,"share":"https://ttm.financial/m/news/2232305878?lang=&edition=fundamental","pubTime":"2022-05-03 21:25","market":"us","language":"en","title":"Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2232305878","media":"seekingalpha","summary":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market ","content":"<html><head></head><body><p></p><p><img src=\"https://static.tigerbbs.com/f4133d165fd1a3872dd4415261977beb\" tg-width=\"750\" tg-height=\"456\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>JuSun/iStock via Getty Images</p><p></p><p>The shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.</p><p><img src=\"https://static.tigerbbs.com/b5783201e2cd8e136a3caa6ee0710d7c\" tg-width=\"868\" tg-height=\"646\" width=\"100%\" height=\"auto\"/></p><p>“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.</p><p>In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.</p><p>Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.</p><p>As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSesen Bio Gains 16% on Plans to Explore Strategic Options Including a Sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-03 21:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives ...</p>\n\n<a href=\"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3830974-sesn-stock-gains-as-company-plans-a-sale","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2232305878","content_text":"JuSun/iStock via Getty ImagesThe shares of Sesen Bio (NASDAQ:SESN) have added 16% in the pre-market Tuesday after the clinical-stage biotech disclosed it started a review of strategic alternatives that will include a sale of the company.“Our strong cash position provides us the opportunity to carefully consider a wide range of potential strategic alternatives designed to maximize shareholder value,” Chief Executive Thomas Cannell said.In addition to an outright sale, the review will include a merger, acquisition, divestiture, or a strategic partnership, the company said, adding that the decision was taken to maximize the shareholder value.Until a deal is finalized, Sesen Bio (SESN) plans to continue its ongoing development efforts, including the studies for its lead asset Vicineum in the treatment of non-muscle-invasive bladder cancer. “We plan to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to an additional Phase 3 clinical trial,” Cannell added.As of March 31, the company reported $169.8 million of cash and cash equivalents with no outstanding debt. The preliminary results are slightly higher than the $162.6 million of cash and cash equivalents reported by Sesen Bio (SESN) at the 2021 year-end.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":485,"commentSize":16,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}